Population pharmacokinetics of exendin‐(9‐39) and clinical dose selection in patients with congenital hyperinsulinism

• Published in: British journal of clinical pharmacology Vol. 84; no. 3; pp. 520 - 532
• Main Authors: Ng, Chee M., Tang, Fei, Seeholzer, Steven H., Zou, Yixuan, De León, Diva D.
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.03.2018
• Subjects: Adolescent; Adult; Age Factors; Animals; Area Under Curve; Child; Child, Preschool; congenital disorders; Congenital Hyperinsulinism - drug therapy; Cross-Over Studies; Dogs; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infant, Newborn; Male; Methods in Clinical Pharmacology; Middle Aged; modelling and simulation; Models, Biological; No-Observed-Adverse-Effect Level; Nonlinear Dynamics; NONMEM; Peptide Fragments - administration & dosage; Peptide Fragments - adverse effects; Peptide Fragments - pharmacokinetics; pharmacokinetics; Pilot Projects; population analysis; Rats; Rats, Sprague-Dawley; Young Adult; pharmacokinetics; modelling and simulation; congenital disorders; population analysis; NONMEM

Aims Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycaemia in infants and children. Exendin‐(9‐39), an inverse glucagon‐like peptide 1 (GLP‐1) agonist, is a novel therapeutic agent for HI that has demonstrated glucose‐raising effect. We report the first population phar...